COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00116064
Recruitment Status : Completed
First Posted : June 27, 2005
Last Update Posted : July 21, 2006
Information provided by:
University of Malawi College of Medicine

Brief Summary:
The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.

Condition or disease Intervention/treatment Phase
Status Epilepticus Convulsions Drug: intranasal lorazepam Drug: intramuscular paraldehyde Phase 3

Detailed Description:
The ideal first line anticonvulsant agent would be one that can be safely and easily given at a primary health care facility. It should be quick acting, have minimal cardiorespiratory side effects and have a relatively prolonged effect and be cheap. No combination of drug or delivery system fully satisfies these criteria. There are no large published studies evaluating intranasal lorazepam in paediatric status epilepticus. Given its favourable pharmacokinetics and potential practical advantages, we wished to assess the efficacy and safety of intranasal delivery of lorazepam compared to intramuscular paraldehyde, our existing first line anticonvulsant agent in the treatment of acute seizures in children.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 156 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children
Study Start Date : July 2004
Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Lorazepam

Primary Outcome Measures :
  1. whether the presenting seizure stopped or not with a single dose of assigned anticonvulsant agent within 10 minutes of administration

Secondary Outcome Measures :
  1. time from drug administration to cessation of convulsion
  2. frequency of episodes requiring 2 or more anticonvulsant agents
  3. continuous blood pressure and oxygen saturation for 30 minutes post drug administration
  4. seizure recurrence within 24 hours of cessation of presenting convulsion
  5. survival/death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children aged between 2 months and 12 years
  • Presenting with generalised convulsions

Exclusion Criteria:

  • Any child who had received an anticonvulsant agent within 1 hour of presentation
  • Seizure stopped with rapid cooling or treatment of hypoglycaemia
  • Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00116064

Layout table for location information
Paediatric Emergency Department, Queen Elizabeth Central Hospital
Blantyre, Malawi
Sponsors and Collaborators
University of Malawi College of Medicine
Layout table for investigator information
Study Director: Elizabeth Molyneux, MRCPCH FFAEM University of Malawi College of Medicine
Principal Investigator: Shafique Ahmad, MRCPCH FFAEM University of Malawi College of Medicine
Publications of Results:
Layout table for additonal information Identifier: NCT00116064    
Other Study ID Numbers: P03/04/248
First Posted: June 27, 2005    Key Record Dates
Last Update Posted: July 21, 2006
Last Verified: June 2005
Keywords provided by University of Malawi College of Medicine:
Additional relevant MeSH terms:
Layout table for MeSH terms
Status Epilepticus
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action